LUBIPROSTONE | A214131 | ZYDUS PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2020-01-28 | Terminated 2020-11-13 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.6460
per ea
Lowest NADAC/Unit
$0.6039
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70710164206LUBIPROSTONE 24 MCG CAPSULE | $0.6460 | EA | Generic | — | 2026-06-17 |
| 70710164106LUBIPROSTONE 8 MCG CAPSULE | $0.6039 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.